Literature DB >> 15655381

Angiotensin-converting enzyme i/d polymorphism in patients with malignant hypertension.

Eugenia Espinel1, Jose Luis Tovar, Javier Borrellas, Luis Piera, Rosendo Jardi, Francisco Rodriguez Frias, Luis Armadans, Ana Gonzalez Bachs.   

Abstract

The angiotensin-converting enzyme (ACE) gene has been implicated in the manifestation of the phenotype of malignant hypertension (MH). In 1990 the ACE gene polymorphism characterized by the insertion or deletion of a 287-base pair fragment in the 17q23 chromosome was identified. The DD genotype is associated with increased tissue and circulating ACE levels and elevated angiotensin II. ACE polymorphism was studied in 48 patients with MH, 25 patients with non-MH, and a control group of 78 normotensive individuals by real-time polymerase chain reaction using the LightCycler system (Roche Diagnostics Corporation, Indianapolis, IN). The DD genotype was found statistically more frequently in MH patients than controls (p=0.028; odds ratio, 2.5; confidence interval, 1.1-5.5). Presence of the DD genotype of the ACE gene is more frequent in MH patients than in controls, indicating that this genotype could be a significant risk factor and a predictor for the development of MH.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15655381      PMCID: PMC8109732          DOI: 10.1111/j.1524-6175.2005.03879.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  26 in total

1.  Genetic mapping of modifier loci affecting malignant hypertension in TGRmRen2 rats.

Authors:  S Kantachuvesiri; C S Haley; S Fleming; K Kurian; C E Whitworth; P Wenham; Y Kotelevtsev; J J Mullins
Journal:  Kidney Int       Date:  1999-08       Impact factor: 10.612

2.  Genetic polymorphism of the renin-angiotensin system and organ damage in essential hypertension.

Authors:  R Pontremoli; M Ravera; F Viazzi; C Nicolella; V Berruti; G Leoncini; F Giacopelli; G P Bezante; G Sacchi; R Ravazzolo; G Deferrari
Journal:  Kidney Int       Date:  2000-02       Impact factor: 10.612

3.  Renin-angiotensin system genetic polymorphisms and cerebral white matter lesions in essential hypertension.

Authors:  Cristina Sierra; Antonio Coca; Elisenda Gómez-Angelats; Esteban Poch; Javier Sobrino; Alejandro de la Sierra
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

4.  Some different types of essential hypertension: their course and prognosis.

Authors:  N M Keith; H P Wagener; N W Barker
Journal:  Am J Med Sci       Date:  1974-12       Impact factor: 2.378

Review 5.  Malignant hypertension: mechanisms and management.

Authors:  P Kincaid-Smith
Journal:  Pharmacol Ther       Date:  1980       Impact factor: 12.310

6.  Understanding malignant hypertension.

Authors:  P Kincaid-Smith
Journal:  Aust N Z J Med       Date:  1981

7.  Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men : the Suita Study.

Authors:  J Higaki; S Baba; T Katsuya; N Sato; K Ishikawa; T Mannami; J Ogata; T Ogihara
Journal:  Circulation       Date:  2000-05-02       Impact factor: 29.690

8.  Hypertensive nephropathy and the gene for angiotensin-converting enzyme.

Authors:  K Kario; N Kanai; S Nishiuma; T Fujii; K Saito; T Matsuo; M Matsuo; K Shimada
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-02       Impact factor: 8.311

9.  Polymorphism of the angiotensin I converting enzyme gene is apparently not related to high blood pressure: Dutch Hypertension and Offspring Study.

Authors:  S Schmidt; I M van Hooft; D E Grobbee; D Ganten; E Ritz
Journal:  J Hypertens       Date:  1993-04       Impact factor: 4.844

10.  Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy.

Authors:  P N Harden; C Geddes; P A Rowe; J H McIlroy; M Boulton-Jones; R S Rodger; B J Junor; J D Briggs; J M Connell; A G Jardine
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

View more
  2 in total

1.  Angiotensin-converting enzyme is a modifier of hypertensive end organ damage.

Authors:  Xiaojun Liu; Christopher O C Bellamy; Matthew A Bailey; Linda J Mullins; Donald R Dunbar; Christopher J Kenyon; Gillian Brooker; Surasak Kantachuvesiri; Klio Maratou; Ali Ashek; Allan F Clark; Stewart Fleming; John J Mullins
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

2.  Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study.

Authors:  Eugenia Espinel; Jorge Joven; Iván Gil; Pilar Suñé; Berta Renedo; Joan Fort; Daniel Serón
Journal:  BMC Res Notes       Date:  2013-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.